These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 28303266

  • 21. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 22. Alternative mechanism of action of the DNP PtIV prodrug: intracellular cisplatin release and the mitochondria-mediated apoptotic pathway.
    Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, Trigub A, Vlasova K, Semkina A, Zyk N, Beloglazkina E, Majouga A.
    Dalton Trans; 2021 Jun 15; 50(23):7922-7927. PubMed ID: 34037020
    [Abstract] [Full Text] [Related]

  • 23. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 24. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
    Gibson D.
    ChemMedChem; 2021 Jul 20; 16(14):2188-2191. PubMed ID: 33928760
    [Abstract] [Full Text] [Related]

  • 25. Electrodrugs: an electrochemical prodrug activation strategy.
    Norman DJ, González-Fernández E, Clavadetscher J, Tucker L, Staderini M, Mount AR, Murray AF, Bradley M.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9242-9245. PubMed ID: 30066701
    [Abstract] [Full Text] [Related]

  • 26. Revisiting Bromohexitols as a Novel Class of Microenvironment-Activated Prodrugs for Cancer Therapy.
    Johansson H, Hussain O, Allison SJ, Robinson TV, Phillips RM, Sejer Pedersen D.
    ChemMedChem; 2020 Jan 17; 15(2):228-235. PubMed ID: 31769617
    [Abstract] [Full Text] [Related]

  • 27. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.
    Petruzzella E, Braude JP, Aldrich-Wright JR, Gandin V, Gibson D.
    Angew Chem Int Ed Engl; 2017 Sep 11; 56(38):11539-11544. PubMed ID: 28759160
    [Abstract] [Full Text] [Related]

  • 28. An oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment.
    Lim WQ, Phua SZF, Chen H, Zhao Y.
    Chem Commun (Camb); 2018 Nov 08; 54(90):12762-12765. PubMed ID: 30370905
    [Abstract] [Full Text] [Related]

  • 29. Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands.
    Navas F, Mendes F, Santos I, Navarro-Ranninger C, Cabrera S, Quiroga AG.
    Inorg Chem; 2017 Jun 05; 56(11):6175-6183. PubMed ID: 28488859
    [Abstract] [Full Text] [Related]

  • 30. ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug.
    Li Y, Shi S, Zhang S, Gan Z, Wang X, Zhao X, Zhu Y, Cao M, Wang X, Li W.
    Dalton Trans; 2021 Aug 28; 50(32):11180-11188. PubMed ID: 34338267
    [Abstract] [Full Text] [Related]

  • 31. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
    Buravchenko GI, Scherbakov AM, Dezhenkova LG, Bykov EE, Solovieva SE, Korlukov AA, Sorokin DV, Monzote Fidalgo L, Shchekotikhin AE.
    Bioorg Chem; 2020 Nov 28; 104():104324. PubMed ID: 33142432
    [Abstract] [Full Text] [Related]

  • 32. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S.
    Bioorg Chem; 2020 Jun 28; 99():103768. PubMed ID: 32217375
    [Abstract] [Full Text] [Related]

  • 33. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M, Gabano E, Bonzani D, Zanellato I, Arrais A, Cantamessa S, Biggiogera M, Osella D.
    J Inorg Biochem; 2018 Dec 28; 189():185-191. PubMed ID: 30312905
    [Abstract] [Full Text] [Related]

  • 34. Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine.
    He S, Li C, Zhang Q, Ding J, Liang XJ, Chen X, Xiao H, Chen X, Zhou D, Huang Y.
    ACS Nano; 2018 Jul 24; 12(7):7272-7281. PubMed ID: 29906087
    [Abstract] [Full Text] [Related]

  • 35. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
    Zheng YR, Suntharalingam K, Johnstone TC, Yoo H, Lin W, Brooks JG, Lippard SJ.
    J Am Chem Soc; 2014 Jun 18; 136(24):8790-8. PubMed ID: 24902769
    [Abstract] [Full Text] [Related]

  • 36. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
    Navas F, Chocarro-Calvo A, Iglesias-Hernández P, Fernández-García P, Morales V, García-Martínez JM, Sanz R, De la Vieja A, García-Jiménez C, García-Muñoz RA.
    J Med Chem; 2024 Apr 25; 67(8):6410-6424. PubMed ID: 38592014
    [Abstract] [Full Text] [Related]

  • 37. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

  • 38. Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
    Pichler V, Mayr J, Heffeter P, Dömötör O, Enyedy ÉA, Hermann G, Groza D, Köllensperger G, Galanksi M, Berger W, Keppler BK, Kowol CR.
    Chem Commun (Camb); 2013 Mar 18; 49(22):2249-2251. PubMed ID: 23396381
    [Abstract] [Full Text] [Related]

  • 39. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 40. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L, Lin X, Li C, Xu Z, Chan CY, Tse MK, Shi P, Zhu G.
    Inorg Chem; 2018 Mar 05; 57(5):2917-2924. PubMed ID: 29436828
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.